ludovic Martinet

List of Publications by Year
in descending order

37 papers	3,775 citations	236925 25 h-index	345221 36 g-index
39 all docs	39 docs citations	39 times ranked	5545 citing authors

#	Article	IF	Citations
1	Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. Blood Advances, 2022, 6, 672-678.	5.2	8
2	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood, 2022, 139, 1160-1176.	1.4	11
3	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity, 2020, 53, 824-839.e10.	14.3	85
4	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	14.3	79
5	Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 3854.	4.1	7
6	Cancer immunoediting and immune dysregulation in multiple myeloma. Blood, 2020, 136, 2731-2740.	1.4	84
7	Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 2019, 3, 1681-1694.	5.2	24
8	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, 4, .	5.0	20
9	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5.	16.8	163
10	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood, 2018, 132, 1689-1694.	1.4	198
11	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discovery, 2016, 6, 446-459.	9.4	198
12	Regulation of Immune Cell Functions through Nectin and Nectin-Like Receptors. , 2016, , 404-414.		4
13	Abstract B155: Anti-CD137 mAb therapy of multiple myeloma. , 2016, , .		0
14	DNAM-1: would the real natural killer cell please stand up!. Oncotarget, 2015, 6, 28537-28538.	1.8	23
15	Balancing natural killer cell activation through paired receptors. Nature Reviews Immunology, 2015, 15, 243-254.	22.7	410
16	NK cells require IL-28R for optimal in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2376-84.	7.1	82
17	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	8.2	111
18	DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation. Cell Reports, 2015, 11, 85-97.	6.4	111

#	Article	IF	Citations
19	Natural Killer cell control ofBRAFV600Emutant melanoma during targeted therapy. OncoImmunology, 2015, 4, e998119.	4.6	5
20	The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nature Immunology, 2014, 15, 431-438.	14.5	410
21	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. Cancer Research, 2014, 74, 7298-7308.	0.9	96
22	DNAMâ€1 control of natural killer cells functions through nectin and nectinâ€like proteins. Immunology and Cell Biology, 2014, 92, 237-244.	2.3	115
23	Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death and Differentiation, 2014, 21, 5-14.	11.2	163
24	High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin Î²â€"Producing Dendritic Cells in Human Breast Cancer. Journal of Immunology, 2013, 191, 2001-2008.	0.8	123
25	Regulation of tumor-associated high-endothelial venules by dendritic cells. OncoImmunology, 2013, 2, e26470.	4.6	12
26	High endothelial venules (HEVs) in human melanoma lesions. OncoImmunology, 2012, 1, 829-839.	4.6	161
27	Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. OncoImmunology, 2012, 1, 789-790.	4.6	39
28	How tumors might withstand Î³Î´ T-cell attack. Cellular and Molecular Life Sciences, 2011, 68, 2433-2442.	5.4	19
29	Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer. Cancer Research, 2011, 71, 5678-5687.	0.9	386
30	Stimulated Î³Î´ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer. Journal of Immunology, 2011, 187, 1031-1038.	0.8	99
31	PGE2 inhibits natural killer and Î³Î´ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochemical Pharmacology, 2010, 80, 838-845.	4.4	108
32	Hospicells derived from ovarian cancer stroma inhibit Tâ€cell immune responses. International Journal of Cancer, 2010, 126, 2143-2152.	5.1	25
33	Phosphoantigens Overcome Human TCRVÎ³9+Î³Î´ Cell Immunosuppression by TGF-Î²: Relevance for Cancer Immunotherapy. Journal of Immunology, 2010, 184, 6680-6687.	0.8	25
34	Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. Journal of Leukocyte Biology, 2009, 85, 553-562.	3.3	89
35	A regulatory crossâ€talk between VÎ³9VÎ´2 T lymphocytes and mesenchymal stem cells. European Journal of Immunology, 2009, 39, 752-762.	2.9	85
36	Pitfalls on the roadmap to Î³Î´ T cell-based cancer immunotherapies. Immunology Letters, 2009, 124, 1-8.	2.5	35

#	Article	IF	Citations
37	Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB Journal, 2006, 20, 2339-2351.	0.5	132